Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18040219 | 0.83 | NOS3 (0.34) | POLBHTR7HTR1AKDM4E | |
| SCHEMBL12102940 | 0.81 | GLS (0.60) | POLBGLSALDH1A1KDM4EGLA | |
| SCHEMBL22505758 | 0.79 | KDM4E (0.41) | POLBHTR7HTR1AALDH1A1KDM4E | |
| SCHEMBL691318 | 0.79 | POLB (0.51) | POLBL3MBTL1GLSCYP1A2MAPK1 | |
| SCHEMBL7113136 | 0.77 | POLB (0.50) | POLBL3MBTL1GLSCYP1A2MAPK1 | |
| SCHEMBL2338357 | 0.76 | POLB (0.49) | POLBL3MBTL1GLSCYP1A2MAPK1 | |
| SCHEMBL29200911 | 0.74 | GLS (0.39) | GLSHTR7HTR1AALDH1A1KDM4E | |
| SCHEMBL11686733 | 0.74 | POLB (0.47) | POLBL3MBTL1GLSCYP1A2MAPK1 | |
| SCHEMBL6128069 | 0.74 | POLB (0.47) | POLBL3MBTL1GLSCYP1A2MAPK1 | |
| SCHEMBL11697399 | 0.74 | L3MBTL1 (0.47) | POLBL3MBTL1GLSCYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332905-A | (S) -N-phenyl-1- (pyridin-2-yl) pyrrolidine-2-carboxamide derivatives | 上海翊石医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-109641882-B | Heteroaromatic derivatives as NIK inhibitors | 杨森制药有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-109641882-A | Heteroaromatic derivatives as NIK inhibitors | 杨森制药有限公司 | 2019-04-16 | — | — | CN | disclosed |
| EP-2468748-B1 | Pyrazoloquinolones are potent parp inhibitors | ABBVIE INC (US) | 2016-05-25 | — | — | EP | disclosed |
| CN-101421268-B | As the pyrazolo quinolone of effective PARP inhibitor | ABBVIE (US) | 2016-01-06 | — | — | CN | disclosed |
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| US-8546368-B2 | Pyrazoloquinolones are potent PARP inhibitors | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2468748-A1 | Pyrazoloquinolones are potent parp inhibitors | Abbott Laboratories (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| CN-101421268-A | Pyrazoloquinolones as potent PARP inhibitors | ABBOTT LAB (US) | 2009-04-29 | — | — | CN | disclosed |
| EP-1989204-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | Abbott Laboratories (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2007095628-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
| US-3966706-A | 2,6-Dihydroxy-3-cyano-4-methylpyridine containing azo dyes which contain a functional amino group | CIBA-GEIGY AG (CH) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | POLB 43/4885L3MBTL1 3332/4885GLS 90/4885 |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | POLB 43/4885L3MBTL1 3332/4885GLS 90/4885 |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | AURKA, AURKB, AURKC | POLB 1199/4885L3MBTL1 801/4885GLS 1980/4885 |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | POLB 1043/4885L3MBTL1 2229/4885GLS 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.